-
公开(公告)号：EP1033989A1
公开(公告)日：2000-09-13
申请号：EP98956356.4
申请日：1998-10-30
IPC分类号： A61K31/56
CPC分类号： A61K31/00 , A61K31/56 , A61K31/566 , A61K31/568 , A61K31/569 , A61K31/57 , A61K31/573 , A61K31/575
摘要： The present invention is directed to a method for reducing mast cell mediated allergic reactions, including mast cell mediated allergy and asthma. Mast cell mediated allergic reactions, including type I hypersensitivity response to allergens and asthma, are reduced by administering a dehydroepiandrosterone (DHEA) derivative to a patient in a manner which quickly raises blood levels of the active agent.
-
-
公开(公告)号：EP4441085A2
公开(公告)日：2024-10-09
申请号：EP22902243.9
申请日：2022-12-02
IPC分类号： C07K14/705 , A61K39/395 , A61P35/00 , C07K16/28
-
-
5.发明公开
公开(公告)号：EP4245347A3
公开(公告)日：2023-12-06
申请号：EP23189866.9
申请日：2012-01-17
摘要： The present disclosure describes systems, methods, and apparatus for reducing the frequency and/or severity of photophobic responses or for modulating circadian cycles by controlling light exposure to melanopsin ganglion cells in a retina over the action potential spectrum of the melanopsin cells of the human eye and a visual spectral response of the human eye. Embodiments of an optical filter are described. In one embodiment an optical filter may be configured to transmit less than a first amount of light weighted across the action potential spectrum of the melanopsin cells and to transmit more than a second amount of light weighted across the visual spectral response. Methods of manufacturing optical filters are also described.
-
公开(公告)号：EP4266952A1
公开(公告)日：2023-11-01
申请号：EP22743088.1
申请日：2022-01-19
-
公开(公告)号：EP4237427A1
公开(公告)日：2023-09-06
申请号：EP21887635.7
申请日：2021-10-29
发明人： SCHMIDT, Eric W. , HAYGOOD, Margo , MILLER, Bailey
-
公开(公告)号：EP4219534A2
公开(公告)日：2023-08-02
申请号：EP22157357.9
申请日：2014-07-07
摘要： An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.
-
-
公开(公告)号：EP4070236A1
公开(公告)日：2022-10-12
申请号：EP20897055.8
申请日：2020-12-01
-
-
-
-
-
-
-
-
-
搜索结果
894 条记录 (耗时 0.021 秒)
